ConductScience.org, home

Paper6135926

Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.

Baum M and 11 others. Lancet, 1983. Cited by 86 papers, by iCite.

Cite this record

ConductScience Library. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Papers, record 6135926. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6135926

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.
PubMed
Journal
Lancet
PubMed
Year
1983
PubMed
Publication types
Clinical Trial, Letter, Randomized Controlled Trial
PubMed
Citations, by iCite
86
iCite
Relative citation ratio, by iCite
1.82
iCite
Revised in PubMed
2019-06-11
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Baum MM
2Brinkley DMD M
3Dossett JAJ A
4McPherson KK
5Patterson JSJ S
6Rubens RDR D
7Smiddy FGF G
8Stoll BAB A
9Wilson AA
10Lea JCJ C
11Richards DD
12Ellis SHS H

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
MastectomyMajor topic
TamoxifenMajor topic
Female
Humans
Postoperative Care

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.

PMIDTitleJournalYearIn PapersSource
41474498Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions.Discov Oncol2025https://conductscience.org/library/papers/41474498PubMed
35626053Evolution of Medical Approaches and Prominent Therapies in Breast Cancer.Cancers (Basel)2022https://conductscience.org/library/papers/35626053PubMed
34398352Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.Breast Cancer Res Treat2021https://conductscience.org/library/papers/34398352PubMed
33825840Estimated Projection of US Cancer Incidence and Death to 2040.JAMA Netw Open2021https://conductscience.org/library/papers/33825840PubMed
28323900Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.PLoS One2017https://conductscience.org/library/papers/28323900PubMed
27986463Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.Cancer Lett2017https://conductscience.org/library/papers/27986463PubMed
26346768Roles for miRNAs in endocrine resistance in breast cancer.Endocr Relat Cancer2015https://conductscience.org/library/papers/26346768PubMed
26278220Progress in adjuvant chemotherapy for breast cancer: an overview.BMC Med2015https://conductscience.org/library/papers/26278220PubMed
26052034The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.Mol Cell Endocrinol2015https://conductscience.org/library/papers/26052034PubMed
24980775Lost in translation: can we afford to miss the trees for the forest?Horm Cancer2014https://conductscience.org/library/papers/24980775PubMed
24659478Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer.Endocr Relat Cancer2014https://conductscience.org/library/papers/24659478PubMed
22042792Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.Cancer Res2011https://conductscience.org/library/papers/22042792PubMed
22017761Male breast carcinoma: increased awareness needed.Breast Cancer Res2011https://conductscience.org/library/papers/22017761PubMed
18068350Tamoxifen: catalyst for the change to targeted therapy.Eur J Cancer2008https://conductscience.org/library/papers/18068350PubMed
16455026Selection of optimal adjuvant endocrine therapy for early-stage breast cancer.Curr Treat Options Oncol2006https://conductscience.org/library/papers/16455026PubMed
15931325NSABP breast cancer clinical trials: recent results and future directions.Clin Med Res2003https://conductscience.org/library/papers/15931325PubMed
12497042Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer?Prostate Cancer Prostatic Dis2001https://conductscience.org/library/papers/12497042PubMed
10463904Contribution of randomised controlled trials to understanding and management of early breast cancer.BMJ1999https://conductscience.org/library/papers/10463904PubMed
6696816Prospects for the future in the management of carcinoma of the breast: the biological fall out from clinical trials.Br J Cancer1984https://conductscience.org/library/papers/6696816PubMed
6381024Current status of chemotherapy of breast cancer.Drugs1984https://conductscience.org/library/papers/6381024PubMed

See all 26 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6135926

GET https://conductscience.org/api/papers/v1/6135926/cited_by?page=2